FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1840834976> ?p ?o ?g. }

• W1840834976 endingPage "258" @default.
• W1840834976 startingPage "243" @default.
• W1840834976 abstract "Objective:To conduct a cost-effectiveness assessment of lenalidomide plus dexamethasone (Rd) vs bortezomib plus melphalan and prednisone (VMP) as initial treatment for transplant-ineligible patients with newly-diagnosed multiple myeloma (MM), from a US payer perspective.Methods:A partitioned survival model was developed to estimate expected life-years (LYs), quality-adjusted LYs (QALYs), direct costs and incremental costs per QALY and LY gained associated with use of Rd vs VMP over a patient’s lifetime. Information on the efficacy and safety of Rd and VMP was based on data from multinational phase III clinical trials and a network meta-analysis. Pre-progression direct costs included the costs of Rd and VMP, treatment of adverse events (including prophylaxis) and routine care and monitoring associated with MM. Post-progression direct costs included costs of subsequent treatment(s) and routine care and monitoring for progressive disease, all obtained from published literature and estimated from a US payer perspective. Utilities were obtained from the aforementioned trials. Costs and outcomes were discounted at 3% annually.Results:Relative to VMP, use of Rd was expected to result in an additional 2.22 LYs and 1.47 QALYs (discounted). Patients initiated with Rd were expected to incur an additional $78,977 in mean lifetime direct costs (discounted) vs those initiated with VMP. The incremental costs per QALY and per LY gained with Rd vs VMP were $53,826 and $35,552, respectively. In sensitivity analyses, results were found to be most sensitive to differences in survival associated with Rd vs VMP, the cost of lenalidomide and the discount rate applied to effectiveness outcomes.Conclusions:Rd was expected to result in greater LYs and QALYs compared with VMP, with similar overall costs per LY for each regimen. Results of this analysis indicated that Rd may be a cost-effective alternative to VMP as initial treatment for transplant-ineligible patients with MM, with an incremental cost-effectiveness ratio well within the levels for recent advancements in oncology." @default.
• W1840834976 created "2016-06-24" @default.
• W1840834976 creator A5003279484 @default.
• W1840834976 creator A5018685925 @default.
• W1840834976 creator A5022520524 @default.
• W1840834976 creator A5046116136 @default.
• W1840834976 creator A5057941456 @default.
• W1840834976 creator A5059990105 @default.
• W1840834976 creator A5068345138 @default.
• W1840834976 creator A5071589084 @default.
• W1840834976 creator A5073964632 @default.
• W1840834976 creator A5081179224 @default.
• W1840834976 creator A5081233146 @default.
• W1840834976 creator A5083639923 @default.
• W1840834976 creator A5084019477 @default.
• W1840834976 creator A5088629560 @default.
• W1840834976 creator A5089511169 @default.
• W1840834976 creator A5089853890 @default.
• W1840834976 date "2015-11-17" @default.
• W1840834976 modified "2023-09-26" @default.
• W1840834976 title "Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma" @default.
• W1840834976 cites W107470920 @default.
• W1840834976 cites W14123024 @default.
• W1840834976 cites W1536569285 @default.
• W1840834976 cites W1585714896 @default.
• W1840834976 cites W1968004526 @default.
• W1840834976 cites W1986382954 @default.
• W1840834976 cites W1990152834 @default.
• W1840834976 cites W1992003712 @default.
• W1840834976 cites W2007584552 @default.
• W1840834976 cites W2020298011 @default.
• W1840834976 cites W2022120598 @default.
• W1840834976 cites W2023234945 @default.
• W1840834976 cites W2040172770 @default.
• W1840834976 cites W2044636425 @default.
• W1840834976 cites W2060909700 @default.
• W1840834976 cites W2069581014 @default.
• W1840834976 cites W2070487839 @default.
• W1840834976 cites W2077906035 @default.
• W1840834976 cites W2083480184 @default.
• W1840834976 cites W2094112454 @default.
• W1840834976 cites W2095950656 @default.
• W1840834976 cites W2096207943 @default.
• W1840834976 cites W2101576302 @default.
• W1840834976 cites W2103289287 @default.
• W1840834976 cites W2104678903 @default.
• W1840834976 cites W2108110723 @default.
• W1840834976 cites W2110466835 @default.
• W1840834976 cites W2123091553 @default.
• W1840834976 cites W2124122050 @default.
• W1840834976 cites W2124560610 @default.
• W1840834976 cites W2133268402 @default.
• W1840834976 cites W2135714170 @default.
• W1840834976 cites W2139672960 @default.
• W1840834976 cites W2141105112 @default.
• W1840834976 cites W2141165931 @default.
• W1840834976 cites W2143024657 @default.
• W1840834976 cites W2145959783 @default.
• W1840834976 cites W2156492908 @default.
• W1840834976 cites W2158106888 @default.
• W1840834976 cites W2163926889 @default.
• W1840834976 cites W2164667231 @default.
• W1840834976 cites W2166394031 @default.
• W1840834976 cites W2170552969 @default.
• W1840834976 cites W2586250428 @default.
• W1840834976 cites W4252175385 @default.
• W1840834976 doi "https://doi.org/10.3111/13696998.2015.1115407" @default.
• W1840834976 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26517601" @default.
• W1840834976 hasPublicationYear "2015" @default.
• W1840834976 type Work @default.
• W1840834976 sameAs 1840834976 @default.
• W1840834976 citedByCount "20" @default.
• W1840834976 countsByYear W18408349762016 @default.
• W1840834976 countsByYear W18408349762017 @default.
• W1840834976 countsByYear W18408349762018 @default.
• W1840834976 countsByYear W18408349762019 @default.
• W1840834976 countsByYear W18408349762020 @default.
• W1840834976 countsByYear W18408349762021 @default.
• W1840834976 countsByYear W18408349762023 @default.
• W1840834976 crossrefType "journal-article" @default.
• W1840834976 hasAuthorship W1840834976A5003279484 @default.
• W1840834976 hasAuthorship W1840834976A5018685925 @default.
• W1840834976 hasAuthorship W1840834976A5022520524 @default.
• W1840834976 hasAuthorship W1840834976A5046116136 @default.
• W1840834976 hasAuthorship W1840834976A5057941456 @default.
• W1840834976 hasAuthorship W1840834976A5059990105 @default.
• W1840834976 hasAuthorship W1840834976A5068345138 @default.
• W1840834976 hasAuthorship W1840834976A5071589084 @default.
• W1840834976 hasAuthorship W1840834976A5073964632 @default.
• W1840834976 hasAuthorship W1840834976A5081179224 @default.
• W1840834976 hasAuthorship W1840834976A5081233146 @default.
• W1840834976 hasAuthorship W1840834976A5083639923 @default.
• W1840834976 hasAuthorship W1840834976A5084019477 @default.
• W1840834976 hasAuthorship W1840834976A5088629560 @default.
• W1840834976 hasAuthorship W1840834976A5089511169 @default.
• W1840834976 hasAuthorship W1840834976A5089853890 @default.
• W1840834976 hasBestOaLocation W18408349761 @default.
• W1840834976 hasConcept C112930515 @default.

• next